Trial Profile
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Peginterferon alfa-2b
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms TIGER
- 12 Dec 2023 Results assessing efficacy and tolerability of nilotinib (NIL) vs NIL+pegylated interferon alpha2b (IFN) combination therapy with IFN maintenance as first-line treatment for patients with chronic myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results assessing the mutation dynamics, longitudinal deep sequencing analysis of serial samples was performed for 100 patients after 12, 24, and 36 months of therapy presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 01 Jun 2022 Status changed from active, no longer recruiting to completed.